

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KATH et al. : Confirmation No.: 8724  
APPLICATION NO.: 10/734,039 : Examiner: V. Balasubramanian  
FILING DATE: December 11, 2003 : Group Art Unit: 1624  
TITLE: COMPOUND FOR THE TREATMENT OF :  
ABNORMAL CELL GROWTH :

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Pfizer Inc. is the owner of 100% interest in the above-captioned application and in application serial number 10/733,215 ("the '215 application"), filed on December 11, 2003; application serial number 11/127,809 ("the '809 application"), filed on May 12, 2005; and application serial number 11/122,515, filed May 5, 2005 ("the '515 application"). Pfizer Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of any patents issuing on said '215, '809 and '515 applications, including any patent term extensions, restorations or adjustments for said patents issuing on said '215, '809 and '515 applications available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patents issuing on said '215, '809 and '515 applications. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such period that the legal title to it and to any patents issuing on said '215, '809 and '515 applications shall be commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patents issuing on said '215, '809 and '515 applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the patents issuing on said '215, '809 and '515 applications expire for failure to pay a maintenance fee, are held unenforceable and/or invalid by a court of competent jurisdiction, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, have all claims canceled by a reexamination certificate, are reissued, or their terms are in any manner shortened prior to the expiration of their full statutory terms as shortened by any terminal disclaimer filed prior to their grant.

This Terminal Disclaimer is accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were

made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date: August 24, 2006

/David L. Kershner/  
David L. Kershner, Ph.D.  
Corporate Counsel  
Reg. No. 53,112  
(212) 733-0538

Pfizer Inc.  
Patent Dept , 5th Fl.  
150 East 42nd Street  
New York, NY 10017-5755